Teladoc Health, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share TDOC The New York Stock Excha

Filing Documents

• tdoc-20251211.htm (8-K) — 23KB
• 0001477449-25-000126.txt ( ) — 172KB
• tdoc-20251211.xsd (EX-101.SCH) — 2KB
• tdoc-20251211_def.xml (EX-101.DEF) — 15KB
• tdoc-20251211_lab.xml (EX-101.LAB) — 26KB
• tdoc-20251211_pre.xml (EX-101.PRE) — 16KB
• tdoc-20251211_htm.xml (XML) — 4KB

From the Filing

tdoc-20251211 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2025 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 155 E 44th Street Suite 1700 New York , NY 10017 (Address of principal executive offices and zip code) ( 203 ) 635-2002 ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 11, 2025, Mr. J. Eric Evans notified Teladoc Health, Inc. (the "Company") of his intention not to stand for reelection at the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting") and to retire from the Board effective as of the conclusion of the Annual Meeting. Mr. Evans has been a director of the Company since 2023 and the Company thanks him for his dedicated service. Mr. Evans has indicated that he is retiring from the Board for personal reasons and not because of any disagreement with the Company on any matter. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 16, 2025 Teladoc Health, Inc. By: /s/ Adam C. Vandervoort Name: Adam C. Vandervoort Title: Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR